Compare Adaptive Biotechnologies Corp (ADPT) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sibanye Stillwater Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Sibanye Stillwater Ltd trades at $8.26 (market cap $5.98B). The key difference: Sibanye Stillwater Ltd is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 3.65% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SBSW | |
|---|---|---|
Market Cap | $3.33B | $5.98B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $21.12 |
52-Week Low | $10.24 | $7.27 |
Enterprise Value | $3.19B | $7.60B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Sibanye Stillwater (SBSW) trades at $8.52, down 4.91% today, with a bearish technical signal and negative earnings trends. The company reported a net loss of $7.30 billion in 2024, though revenue remains substantial at $112.13 billion. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, but profitability challenges persist.
The outlook is mixed: low valuation multiples suggest potential upside if operational turnaround succeeds, but negative margins and high debt pose significant risks. Analyst sentiment leans bullish with 42.86% buy ratings, yet recent earnings misses and cash flow volatility warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
